Your browser is no longer supported. Please, upgrade your browser.
GLYC GlycoMimetics, Inc. daily Stock Chart
GlycoMimetics, Inc.
Index- P/E- EPS (ttm)-1.11 Insider Own0.20% Shs Outstand42.81M Perf Week5.10%
Market Cap600.20M Forward P/E- EPS next Y-1.14 Insider Trans-40.18% Shs Float42.47M Perf Month0.79%
Income-40.00M PEG- EPS next Q-0.31 Inst Own- Short Float17.78% Perf Quarter-11.88%
Sales- P/S- EPS this Y24.30% Inst Trans-0.28% Short Ratio24.62 Perf Half Y-22.24%
Book/sh5.33 P/B2.63 EPS next Y8.80% ROA-22.00% Target Price28.00 Perf Year23.96%
Cash/sh- P/C- EPS next 5Y- ROE-23.00% 52W Range10.25 - 26.05 Perf YTD-16.50%
Dividend- P/FCF- EPS past 5Y-18.80% ROI- 52W High-46.18% Beta3.01
Dividend %- Quick Ratio33.10 Sales past 5Y- Gross Margin- 52W Low36.78% ATR0.60
Employees40 Current Ratio33.10 Sales Q/Q- Oper. Margin- RSI (14)50.00 Volatility4.35% 3.92%
OptionableYes Debt/Eq0.00 EPS Q/Q11.90% Profit Margin- Rel Volume0.99 Prev Close13.51
ShortableYes LT Debt/Eq0.00 EarningsNov 08 AMC Payout- Avg Volume306.76K Price14.02
Recom1.60 SMA20-0.47% SMA50-3.47% SMA200-19.67% Volume305,398 Change3.77%
Jul-26-16Initiated SunTrust Buy
Mar-17-15Reiterated Stifel Buy $13 → $14
Oct-10-18 04:54PM  Neurocrine Inks Deal with Private Biotech to Make CNS Drugs Zacks
Aug-31-18 07:45AM  Research Report Identifies FS Investment, Rush Enterprises, GlycoMimetics, Federal Signal, ATN International, and Novavax with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Aug-29-18 04:00AM  Edited Transcript of GLYC earnings conference call or presentation 10-Aug-18 12:30pm GMT Thomson Reuters StreetEvents
Aug-14-18 09:00AM  GlycoMimetics Receives Japanese Patent For Uproleselan (GMI-1271) Business Wire
Aug-10-18 10:15PM  GlycoMimetics (GLYC) Q2 2018 Earnings Conference Call Transcript Motley Fool
03:17PM  GlycoMimetics Stock Has Substantial Upside InvestorPlace
06:30AM  GlycoMimetics, Inc. to Host Earnings Call ACCESSWIRE
Aug-09-18 04:49PM  GlycoMimetics: 2Q Earnings Snapshot Associated Press
04:05PM  GlycoMimetics Reports Second Quarter 2018 Results and Highlights Recent Company Achievements Business Wire
Aug-02-18 09:00AM  GlycoMimetics to Report Second Quarter 2018 Financial Results on August 9, 2018 Business Wire
Jul-27-18 07:50AM  Factors of Influence in 2018, Key Indicators and Opportunity within Minerals Technologies, USG, Continental Resources, Take-Two Interactive Software, Trimble, and GlycoMimetics New Research Emphasizes Economic Growth GlobeNewswire
Jul-18-18 07:20AM  Free Daily Technical Summary Reports on Iovance Biotherapeutics and Three Other Biotech Stocks ACCESSWIRE
Jun-14-18 07:05AM  Free Technical Reports on Gilead Sciences and Three Additional Biotech Equities ACCESSWIRE -6.06%
Jun-01-18 04:15PM  GlycoMimetics to Present at Jefferies 2018 Global Healthcare Conference Business Wire
May-30-18 09:15AM  GlycoMimetics Announces NCI-Sponsored Pivotal Trial of GMI-1271 in Older, Newly Diagnosed AML Patients Fit for Intensive Chemotherapy Business Wire
May-22-18 08:15AM  New Research Coverage Highlights Apollo Commercial Real Estate Finance, Drive Shack, GlycoMimetics, Dycom Industries, Apple Hospitality REIT, and Howard Hughes Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
May-03-18 04:05PM  Edited Transcript of GLYC earnings conference call or presentation 3-May-18 12:30pm GMT Thomson Reuters StreetEvents -6.49%
08:46AM  GlycoMimetics: 1Q Earnings Snapshot Associated Press
07:00AM  GlycoMimetics Reports First Quarter 2018 Results Business Wire
Apr-26-18 09:00AM  GlycoMimetics to Report First Quarter 2018 Financial Results on May 3, 2018 Business Wire
Mar-29-18 08:20AM  New Research Coverage Highlights Healthcare Trust of America, Drive Shack, Chemed, AMERISAFE, Medical Properties Trust, and GlycoMimetics Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Mar-20-18 09:24PM  GlycoMimetics Announces Pricing of Public Offering of Common Stock Business Wire
Mar-19-18 04:01PM  GlycoMimetics Announces Proposed Public Offering of Common Stock Business Wire -5.73%
Mar-14-18 05:55PM  GlycoMimetics to Present New Preclinical Data for GMI-1271 and GMI-1359 at AACR Annual Meeting 2018 Business Wire
Mar-07-18 09:00AM  GlycoMimetics to Present at Four Investor Conferences This Month Business Wire
Mar-06-18 10:16PM  Edited Transcript of GLYC earnings conference call or presentation 6-Mar-18 1:30pm GMT Thomson Reuters StreetEvents -17.84%
02:48PM  Why GlycoMimetics Is Tumbling 19.2% Today Motley Fool
08:30AM  Todays Research Reports on Trending Tickers: GlycoMimetics, Inc. and Vericel Corporation ACCESSWIRE
07:51AM  GlycoMimetics reports 4Q loss Associated Press
07:30AM  GlycoMimetics Reports Fourth Quarter and Year-End 2017 Results Business Wire
06:00AM  GlycoMimetics, Inc. to Host Earnings Call ACCESSWIRE
Mar-05-18 04:01PM  GlycoMimetics Announces Design of Phase 3 Clinical Trial for GMI-1271 in Relapsed/Refractory AML Business Wire -5.90%
01:39PM  When Can We Expect A Profit From GlycoMimetics Inc (NASDAQ:GLYC)? Simply Wall St.
08:35AM  Should You Buy GlycoMimetics (GLYC) Ahead of Earnings? Zacks
Feb-27-18 09:00AM  GlycoMimetics to Report Fourth Quarter and Year-End 2017 Financial Results on March 6, 2018 Business Wire
Feb-08-18 09:00AM  GlycoMimetics Enters into Agreement with HOVON to Initiate Study Startup Activities for Planned Clinical Trial of GMI-1271 and Decitabine in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Chemotherapy Business Wire -7.48%
Jan-26-18 07:45AM  New Research: Key Drivers of Growth for NanoString Technologies, Oaktree Capital Group, Midstates Petroleum, GlycoMimetics, State Street, and Retail Properties of America Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Jan-15-18 06:11AM  What Is GlycoMimetics Incs (NASDAQ:GLYC) Financial Position? Simply Wall St.
Jan-14-18 09:00AM  5 Biotech Stocks That Could Be Bought Out in 2018 Motley Fool
Jan-02-18 06:29AM  Has GlycoMimetics Incs (NASDAQ:GLYC): Earnings Momentum Changed Lately? Simply Wall St.
Dec-17-17 09:00AM  Here's Why GlycoMimetics Could Become a Takeover Target Motley Fool
Dec-15-17 09:00AM  GlycoMimetics Added To NASDAQ Biotechnology Index Business Wire
Dec-14-17 01:44PM  These 4 stocks are powering higher MarketWatch
Dec-13-17 09:16AM  Company News For Dec 13, 2017 Zacks
Dec-12-17 04:59PM  Why This Biotech Stock Is Defying A Hematology-Related Pitfall Investor's Business Daily +14.87%
12:39PM  Here's Why GlycoMimetics Is Soaring 24.3% Higher Today Motley Fool
07:42AM  UPDATE: GlycoMimetics shares soar 30% after positive trial of leukemia treatment MarketWatch
07:00AM  GlycoMimetics Reports Improvements in Median Overall Survival Versus Historical Matched Controls for Two AML Patient Subgroups in Phase 1/2 Trial for GMI-1271 Business Wire
Dec-06-17 09:07AM  The Zacks Analyst Blog Highlights: Sangamo Therapeutics, Sarepta Therapeutics, Akebia Therapeutics, Calithera Biosciences and GlycoMimetics Zacks
Dec-05-17 08:09AM  5 Top-Ranked Drug Stocks that are Broker Favorites Zacks
Nov-28-17 08:36AM  GlycoMimetics (GLYC) Jumps: Stock Rises 11.9% Zacks
Nov-27-17 12:20PM  What Is GlycoMimetics Incs (GLYC) Share Price Doing? Simply Wall St. +11.92%
Nov-09-17 09:15AM  GlycoMimetics to Present at Upcoming Healthcare Investor Conferences Business Wire
Nov-08-17 02:36PM  Edited Transcript of GLYC earnings conference call or presentation 8-Nov-17 1:30pm GMT Thomson Reuters StreetEvents +8.60%
07:35AM  GlycoMimetics reports 3Q loss Associated Press
07:30AM  GlycoMimetics Reports Program Updates and Third Quarter 2017 Results Business Wire
06:50AM  GlycoMimetics, Inc. to Host Earnings Call ACCESSWIRE
Nov-02-17 08:36AM  Why Earnings Season Could Be Great for GlycoMimetics (GLYC) Zacks +7.95%
Nov-01-17 09:25AM  GlycoMimetics to Report Third-Quarter 2017 Financial Results on November 8, 2017 Business Wire
09:18AM  GlycoMimetics to Highlight GMI-1271 Clinical Data and Underlying, Differentiated Mechanism of Action in Oral Presentations at 59th Annual ASH Meeting Business Wire
Oct-17-17 10:12AM  GlycoMimetics, Inc. Value Analysis (NASDAQ:GLYC) : October 17, 2017 Capital Cube
Oct-16-17 08:34AM  GlycoMimetics, Inc. breached its 50 day moving average in a Bearish Manner : GLYC-US : October 16, 2017 Capital Cube
Sep-26-17 08:57AM  GlycoMimetics (GLYC) in Focus: Stock Moves 9.2% Higher Zacks -6.46%
Sep-11-17 10:39AM  GlycoMimetics, Inc. breached its 50 day moving average in a Bearish Manner : GLYC-US : September 11, 2017 Capital Cube
Sep-05-17 09:00AM  GlycoMimetics to Present at Biocenturys Newsmakers in the Biotech Industry Conference Business Wire
08:47AM  Can GlycoMimetics (GLYC) Run Higher on Strong Earnings Estimate Revisions? Zacks
Aug-25-17 08:36AM  GlycoMimetics, Inc. breached its 50 day moving average in a Bullish Manner : GLYC-US : August 25, 2017 Capital Cube
Aug-08-17 08:22AM  GlycoMimetics, Inc. breached its 50 day moving average in a Bullish Manner : GLYC-US : August 8, 2017 Capital Cube
Aug-04-17 03:17AM  GlycoMimetics reports 2Q loss Associated Press
Aug-03-17 09:15AM  GlycoMimetics Reports Program Updates and Second Quarter 2017 Results Business Wire
Aug-01-17 06:28PM  GlycoMimetics, Inc. Value Analysis (NASDAQ:GLYC) : August 1, 2017 Capital Cube
Jul-19-17 08:23AM  GlycoMimetics, Inc. breached its 50 day moving average in a Bullish Manner : GLYC-US : July 19, 2017 Capital Cube
Jul-06-17 09:00AM  GlycoMimetics to Receive European Patent for GMI-1271 Business Wire
Jun-30-17 09:00AM  Are Options Traders Betting on a Big Move in GlycoMimetics (GLYC) Stock? Zacks
Jun-12-17 09:00AM  GlycoMimetics Appoints Boston Biomedical CEO Patricia S. Andrews to Its Board of Directors Business Wire
Jun-07-17 08:00AM  Today's Research Reports on Top Tech Stocks: GlycoMimetics and Acorda Therapeutics Accesswire -6.18%
Jun-05-17 04:00PM  GlycoMimetics to Present at Jefferies 2017 Global Healthcare Conference Business Wire -14.47%
12:47PM  Why GlycoMimetics Is Tumbling 13.4% Today Motley Fool
07:00AM  GlycoMimetics Presents Updated Data from Ongoing Phase 1/2 Clinical Trial of GMI-1271 in Patients with Acute Myeloid Leukemia at ASCO 2017 Annual Meeting Business Wire
May-31-17 09:00AM  GlycoMimetics Completes Enrollment of Relapsed/Refractory AML Patient Cohort in Phase 2 Portion of Clinical Trial of GMI-1271 Business Wire -5.44%
May-30-17 04:00PM  GlycoMimetics Announces Closing of Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire
May-25-17 04:01PM  Here's Why GlycoMimetics Rose as Much as 21% Today Motley Fool
09:25AM  GlycoMimetics GMI-1271 Receives EU Orphan Drug Designation for Acute Myeloid Leukemia Business Wire
May-24-17 08:00AM  GlycoMimetics Announces Pricing of Public Offering of Common Stock Business Wire +5.66%
May-23-17 11:11AM  Shark Bites: There Wasn't Even a Dip to Buy +20.35%
May-22-17 04:01PM  GlycoMimetics Announces Proposed Public Offering of Common Stock Business Wire -13.71%
08:00AM  Today's Research Reports on Biotech Stocks to Watch: Arena Pharmaceuticals and GlycoMimetics Accesswire
May-19-17 01:55PM  ETFs with exposure to GlycoMimetics, Inc. : May 19, 2017 Capital Cube +19.59%
01:28PM  Why GlycoMimetics Is Ripping 19% Higher Today Motley Fool
08:35AM  GlycoMimetics (GLYC) Shows Strength: Stock Jumps 98.7% Zacks
08:00AM  Today's Research Reports on Stocks to Watch: GlycoMimetics and Endologix Accesswire
May-18-17 03:15PM  Here's Why GlycoMimetics (GLYC) Stock Skyrocketed Over 100% Today Zacks +98.70%
10:57AM  Don't Trust the Bounce Yet
06:30AM  GlycoMimetics Announces High Overall Response Rates, Low Induction Mortality, Promising Initial Survival Outcomes, and Supportive Biomarker Data from Phase 1/2 Trial of GMI-1271 in AML Business Wire
May-17-17 04:10PM  GlycoMimetics GMI-1271 Receives FDA Breakthrough Therapy Designation for Adult Relapsed/Refractory Acute Myeloid Leukemia Business Wire
May-08-17 09:04AM  GlycoMimetics reports 1Q loss Associated Press
09:00AM  GlycoMimetics Reports Program Updates and First Quarter 2017 Results Business Wire
May-02-17 09:00AM  GlycoMimetics Announces Publication of Preclinical Data Showing Role of E-selectin Ligands in Multiple Myeloma Business Wire
Apr-20-17 10:44AM  GlycoMimetics to Present New AML Clinical Data at ASCO 2017 Annual Meeting Business Wire
Apr-05-17 04:49PM  ETFs with exposure to GlycoMimetics, Inc. : April 5, 2017 Capital Cube
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. Its advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and has evaluated in a Phase 3 clinical trial, conducted by its strategic collaboration with Pfizer Inc. The company's drug candidate, GMI-1271, an E-selectin antagonist, is evaluated in a Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia and is in a Phase 1 clinical trial for the treatment of multiple myeloma. It is also developing a Phase 1 clinical trial drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. It has a cooperative research and development agreement with the National Cancer Institute. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hahn Brian M.CFOJun 11Option Exercise1.125,2605,89119,345Jun 12 05:54 PM
Hahn Brian M.CFOJun 11Sale18.0419,345348,9840Jun 12 05:54 PM
Magnani John L.SVP of Research, CSOMay 23Option Exercise0.331,491492100,793May 24 05:11 PM
SANDELL SCOTT D10% OwnerMay 10Sale17.819,539169,8904,702,791May 11 05:02 PM
BARRIS PETER J10% OwnerMay 10Sale17.819,539169,8904,702,791May 11 05:01 PM
BARRETT M JAMESDirectorMay 10Sale17.819,539169,8904,702,791May 11 05:00 PM
NEW ENTERPRISE ASSOCIATES 10 L10% OwnerMay 10Sale17.819,539169,8904,702,791May 11 05:00 PM
Thackray Helen M.SVP Clinical Development, CMODec 08Sale15.012,00030,020148,615Dec 12 04:14 PM